Tafasitamab with lenalidomide and rituximab for new lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (tafasitamab, lenalidomide, and rituximab) for people with newly diagnosed follicular or marginal zone lymphoma who have not had treatment before. The goal is to see if this combination works well and is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have follicular lymphoma (grade 1, 2, or 3a) or marginal zone lymphoma confirmed by a biopsy.
- You cannot have had any prior treatment for lymphoma, such as chemotherapy or immunotherapy.
- Your lymphoma must be causing symptoms that need treatment, like a large tumor, fevers, night sweats, weight loss, or other problems, or you must have a high FLIPI2 score.
- You must have good organ function (kidney, liver, heart, lungs) and be willing to use birth control if needed.
- You cannot have active hepatitis B, hepatitis C, or HIV, or have had a blood clot or stroke in the last year.
- You must be able to take blood thinners while on the study drug lenalidomide.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two drugs (rituximab and tafasitamab) with donor natural killer (NK) cells to treat B-cell non-Hodgkin lymphoma that has come back or stopped responding to prior treatments. The goal is to see if this combination can help the immune system fight the cancer more effectively.
This trial tests a combination of three medications (orelabrutinib, tafasitamab, and lenalidomide) for newly diagnosed follicular lymphoma. The goal is to see if this combination can help control the cancer effectively.
This trial tests a combination of three drugs (epcoritamab, zanubrutinib, and rituximab) for people with follicular lymphoma or marginal zone lymphoma that has come back after at least one prior treatment. The goal is to see if this new combination is safe and effective.
This phase 2 trial tests whether a combination of epcoritamab plus rituximab can work as a first treatment for follicular lymphoma. It may help people whose lymphoma is causing symptoms or affecting organs, or who have bulky disease, by targeting the lymphoma cells.
This Phase 2 study tests whether loncastuximab, combined with rituximab, can shrink and control follicular lymphoma that has come back or not responded to prior treatment. It may help people who still have active disease that needs treatment and meet specific scan and blood test requirements.
This Phase 2 trial studies tafasitamab together with lenalidomide and venetoclax in people with mantle cell lymphoma (MCL) that has come back or did not respond to prior treatment. It may help shrink the lymphoma and improve disease control when standard options have not worked.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.